# BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes

> **NCT05161429** · — · UNKNOWN · sponsor: **Brigham and Women's Hospital** · enrollment: 550000 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** DPP4
- **DRUG:** GLP-1 receptor agonist
- **DRUG:** Basal Insulin
- **DRUG:** SLGT2
- **DRUG:** SU

## Key facts

- **NCT ID:** NCT05161429
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-01
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 550000 (ESTIMATED)
- **Last updated:** 2023-06-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05161429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05161429, "BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05161429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*